Rare Tumor News
Recent news about the MyPART program and other updates in the study of rare tumors.
The U.S. Food and Drug Administration (FDA) announced on December 9th, 2022 that the immunotherapy drug atezolizumab was approved for the treatment of patients 2 years and older with ASPS that has spread to other parts of the body or cannot be removed by surgery.
The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis type 1 (NF1) and tumors called plexiform neurofibromas. Read the full blog post published by NCI Staff on April 14, 2020.
MyPART, Center for Cancer Research, and the Chordoma Foundation collaborated to host the first childhood, teen, and young adult Chordoma Clinic at NIH from April 16th to 18th, 2019. The clinic aimed to share knowledge and to collect data for research on chordoma affecting young people.